Prolonged high-dose omalizumab is required to control reactions to venom immunotherapy in mastocytosis

Authors

  • K. Kontou-Fili,

    Corresponding author
      *Chief Allergology Department
      Euroclinic Hospital
      8 Fidippidou st. Athens 11526
      Hellas (Gr)
      Athens
      Greece
      Tel.: +30 2107774666; ++30 6932421516
      Fax: +30 2106010842
      Email: kontoufk@otenet.gr
    Search for more papers by this author
  • C. I. Filis


  • High Omalizumab dose, administered at strictly 30-day intervals, controls venom immunotherapy reactions in systemic mastocytosis.

*Chief Allergology Department
Euroclinic Hospital
8 Fidippidou st. Athens 11526
Hellas (Gr)
Athens
Greece
Tel.: +30 2107774666; ++30 6932421516
Fax: +30 2106010842
Email: kontoufk@otenet.gr

No abstract is available for this article.

Ancillary